Shopping Cart
Remove All
Your shopping cart is currently empty
Befovacimab (Synonyms: BAY 1093884)
Catalog No. T76921 Copy Product Info
🥰Excellent
Befovacimab (BAY 1093884) is a fully human monoclonal antibody directed against tissue factor pathway inhibitor (TFPI). By blocking the inhibitory activity of TFPI on Factor Xa and the tissue factor-Factor VIIa (TF-VIIa) complex, it restores thrombin generation, holding significant potential for the treatment research of Hemophilia A and B.
Befovacimab
Copy Product Info🥰Excellent
Catalog No. T76921
Synonyms BAY 1093884
Befovacimab (BAY 1093884) is a fully human monoclonal antibody directed against tissue factor pathway inhibitor (TFPI). By blocking the inhibitory activity of TFPI on Factor Xa and the tissue factor-Factor VIIa (TF-VIIa) complex, it restores thrombin generation, holding significant potential for the treatment research of Hemophilia A and B.
Befovacimab
Cas No. 2156634-62-5
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Befovacimab (BAY 1093884) is a fully human monoclonal antibody directed against tissue factor pathway inhibitor (TFPI). By blocking the inhibitory activity of TFPI on Factor Xa and the tissue factor-Factor VIIa (TF-VIIa) complex, it restores thrombin generation, holding significant potential for the treatment research of Hemophilia A and B. |
| Targets&IC50 | TFPI:4.65 nM |
| In vitro | Befovacimab binds with high affinity (<10 pM) to the K1 and K2 domains of human TFPI, inhibiting its interaction with Factor Xa (FXa) and FVIIa, thereby successfully restoring their biological activities [2]. |
| In vivo | In female cynomolgus monkeys, IV or SC administration of Befovacimab (5 and 20 mg/kg) dose-dependently reduces systemic TFPI levels and shortens clotting time. In monkey plasma, the IC50 values for inhibiting free TFPI and shortening diluted prothrombin time (dPT) are 4.65 nM and 6.19 nM, respectively [2]. |
| Synonyms | BAY 1093884 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | TFPI |
| Cas No. | 2156634-62-5 |
| Isotype | IgG2SA |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Befovacimab | purchase Befovacimab | Befovacimab cost | order Befovacimab | Befovacimab in vivo | Befovacimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.